<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163139">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01929096</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-23-01</org_study_id>
    <nct_id>NCT01929096</nct_id>
  </id_info>
  <brief_title>Compound Edaravone Injection for Acute Ischemic Stroke</brief_title>
  <official_title>Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Multi-dose, Parallel, and Controlled Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To investigate the efficacy and safety of multi-doses Compound Edaravone Injection
           versus Edaravone Injection for acute ischemic stroke patients;

        2. To provide evidence for the design of Compound Edaravone Injection Phase III trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>mRS score on day 90</measure>
    <time_frame>day 90</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline NIHSS score on day 14</measure>
    <time_frame>day 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with NIHSS score 0-1 (including motor function) on day 14, 30, 90</measure>
    <time_frame>day 14, 30, 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with Barthel Index (BI) score greater than or equal to 95 on day 14, 30, 90</measure>
    <time_frame>day 14, 30, 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Montreal Cognitive Assessment(MoCA) score on day 14, 30, 90</measure>
    <time_frame>day 14, 30, 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Impact Scale (SIS) score on day 90</measure>
    <time_frame>day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Low-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound Edaravone Injection, 12.5mg/dose (Edaravone 10mg, (+)-Borneol 2.5mg), one dose every 12 hours, continue for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound Edaravone Injection, 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound Edaravone Injection, 62.5mg/dose (Edaravone 50mg, (+)-Borneol 12.5mg), one dose every 12 hours, continue for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Edaravone Injection，30 mg/dose, one dose every 12 hours, continues for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound Edaravone Injection</intervention_name>
    <arm_group_label>Low-dose group</arm_group_label>
    <arm_group_label>Medium-dose group</arm_group_label>
    <arm_group_label>High-dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone Injection</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized patients, diagnosed of ischemic stroke;

          -  Onset of stroke is less than or equal to 48 hours;

          -  There are clear signs of neurological deficit: 4≤NIHSS score≤24, and also, the sum of
             NIHSS score for the upper limb and the lower limb is greater than or equal to 2;

          -  Patients signed written inform consent.

        Exclusion Criteria:

          -  Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural
             hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid
             hemorrhage;

          -  Iatrogenic stroke;

          -  Severe disturbance of consciousness: NIHSS category 1a for consciousness is greater
             than 1；

          -  The mRS score prior to this onset is greater than 1;

          -  Transient ischemic attack (TIA);

          -  SBP after blood pressure control is still greater than to equal to 220 mmHg, or DBP
             after blood pressure control is still greater than or equal to 120 mmHg;

          -  Patients with severe mental disorders and dementia;

          -  ALT or AST is greater than 2.0×ULN or previously known liver diseases, such as acute
             hepatitis, chronic active hepatitis, liver cirrhosis;

          -  Creatinine clearance is less than 30 ml/min or previously known severe renal
             diseases;

          -  Therapeutic neuroprotective agents have been applied after onset, including
             commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam,
             butyl benzene peptides, Urinary Kallidinogenase;

          -  Arterial or venous thrombolytic therapy has been applied after onset;

          -  With malignant tumors or receiving concurrent antitumor treatment;

          -  With severe systemic disease, life expectancy is less than 90 days;

          -  Pregnant or lactating women;

          -  Participate in other clinical studies within 30 days before randomization;

          -  The investigators consider the patients are not suitable for this trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongjun Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjun Wang, MD</last_name>
      <phone>86-010-67096611</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 22, 2013</lastchanged_date>
  <firstreceived_date>August 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Phenylmethylpyrazolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
